Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 169Carcinoma, Neuroendocrine 73Thyroid Neoplasms 52Pheochromocytoma 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Adrenocortical Carcinoma 40Carcinoid Tumor 39Paraganglioma 35Adenocarcinoma, Follicular 33Neoplasm Metastasis 29Neoplasms 28Somatostatinoma 26Adenoma, Islet Cell 26Insulinoma 22Carcinoma, Medullary 22Carcinoma, Islet Cell 22Pancreatic Neoplasms 21Pituitary Neoplasms 20Sarcoma 19Glucagonoma 19Gastrinoma 19Gastro-enteropancreatic neuroendocrine tumor 16Head and Neck Neoplasms 15Colorectal Neoplasms 14Multiple Endocrine Neoplasia Type 1 13Neuroblastoma 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Vipoma 11

Interventions

vandetanib 1lenvatinib 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid cancer, medullary × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡